AU4766096A - Anti-obesity proteins - Google Patents

Anti-obesity proteins

Info

Publication number
AU4766096A
AU4766096A AU47660/96A AU4766096A AU4766096A AU 4766096 A AU4766096 A AU 4766096A AU 47660/96 A AU47660/96 A AU 47660/96A AU 4766096 A AU4766096 A AU 4766096A AU 4766096 A AU4766096 A AU 4766096A
Authority
AU
Australia
Prior art keywords
obesity proteins
obesity
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU47660/96A
Inventor
Margaret B Basinski
Richard D. Dimarchi
David B Flora
William F. Heath Jr.
James A Hoffmann
Brigitte E Schoner
James E Shields
David L Smiley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/381,054 external-priority patent/US5569743A/en
Priority claimed from US08/381,049 external-priority patent/US5574133A/en
Priority claimed from US08/381,034 external-priority patent/US5532336A/en
Priority claimed from US08/381,050 external-priority patent/US5563244A/en
Priority claimed from US08/381,041 external-priority patent/US5567678A/en
Priority claimed from US08/381,037 external-priority patent/US5563243A/en
Priority claimed from US08/381,370 external-priority patent/US5525705A/en
Priority claimed from US08/381,666 external-priority patent/US5521283A/en
Priority claimed from US08/381,163 external-priority patent/US5563245A/en
Priority claimed from US08/381,040 external-priority patent/US5552522A/en
Priority claimed from US08/381,057 external-priority patent/US5580954A/en
Priority claimed from US08/383,650 external-priority patent/US5691309A/en
Priority claimed from US08/383,632 external-priority patent/US5569744A/en
Priority claimed from US08/383,649 external-priority patent/US5567803A/en
Priority claimed from US08/384,492 external-priority patent/US5594104A/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU4766096A publication Critical patent/AU4766096A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU47660/96A 1995-01-31 1996-01-29 Anti-obesity proteins Abandoned AU4766096A (en)

Applications Claiming Priority (39)

Application Number Priority Date Filing Date Title
US381266 1982-05-24
US381057 1989-07-17
US383632 1989-07-24
US38145195A 1995-01-31 1995-01-31
US38126695A 1995-01-31 1995-01-31
US38104795A 1995-01-31 1995-01-31
US38124795A 1995-01-31 1995-01-31
US08/381,049 US5574133A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,057 US5580954A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,041 US5567678A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,037 US5563243A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381247 1995-01-31
US381047 1995-01-31
US381666 1995-01-31
US08/381,370 US5525705A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381034 1995-01-31
US381049 1995-01-31
US381451 1995-01-31
US08/381,666 US5521283A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,054 US5569743A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381370 1995-01-31
US08/381,034 US5532336A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,050 US5563244A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US08/381,040 US5552522A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381054 1995-01-31
US381040 1995-01-31
US08/381,163 US5563245A (en) 1995-01-31 1995-01-31 Anti-obesity proteins
US381163 1995-01-31
US381050 1995-01-31
US381041 1995-01-31
US381037 1995-01-31
US08/383,650 US5691309A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
US383649 1995-02-06
US383650 1995-02-06
US384492 1995-02-06
US08/383,632 US5569744A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
US08/383,649 US5567803A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
US08/384,492 US5594104A (en) 1995-01-31 1995-02-06 Anti-obesity proteins
PCT/US1996/000947 WO1996023514A1 (en) 1995-01-31 1996-01-29 Anti-obesity proteins

Publications (1)

Publication Number Publication Date
AU4766096A true AU4766096A (en) 1996-08-21

Family

ID=27586325

Family Applications (1)

Application Number Title Priority Date Filing Date
AU47660/96A Abandoned AU4766096A (en) 1995-01-31 1996-01-29 Anti-obesity proteins

Country Status (5)

Country Link
EP (1) EP0836620A1 (en)
JP (1) JPH11501297A (en)
AU (1) AU4766096A (en)
CA (1) CA2211656A1 (en)
WO (1) WO1996023514A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
US6429290B1 (en) 1994-08-17 2002-08-06 The Rockefeller University OB polypeptides, modified forms and derivatives
GB9509164D0 (en) 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
WO1997016550A1 (en) * 1995-11-02 1997-05-09 Bristol-Myers Squibb Company Polypeptide fragments derived from the obese gene product
AU730501B2 (en) * 1996-04-23 2001-03-08 Novozymes A/S Animal feed additives
JP2000512137A (en) * 1996-06-06 2000-09-19 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー Fragment of leptin (ob protein)
WO1998016545A1 (en) * 1996-10-11 1998-04-23 Eli Lilly And Company Therapeutic proteins
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
DK1444516T3 (en) 2001-10-22 2010-11-15 Amgen Inc Use of leptin in the treatment of human lipoatrophy and method for determining a predisposition for this treatment
US7105526B2 (en) 2002-06-28 2006-09-12 Banyu Pharmaceuticals Co., Ltd. Benzimidazole derivatives
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
ATE547404T1 (en) 2003-09-22 2012-03-15 Msd Kk PIPERIDINE DERIVATIVES
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
US7737155B2 (en) 2005-05-17 2010-06-15 Schering Corporation Nitrogen-containing heterocyclic compounds and methods of use thereof
NZ562766A (en) 2005-05-30 2011-03-31 Banyu Pharma Co Ltd Piperidine derivatives as histamine-H3 receptor antagonists
JPWO2007018248A1 (en) 2005-08-10 2009-02-19 萬有製薬株式会社 Pyridone compounds
US7875633B2 (en) 2005-08-24 2011-01-25 Banyu Pharmaceutical Co., Ltd. Phenylpyridone derivative
US8227408B2 (en) 2005-09-07 2012-07-24 Neurotez, Inc. Leptin as an anti-amyloidogenic biologic and methods for delaying the onset and reducing Alzheimer's disease-like pathology
JPWO2007029847A1 (en) 2005-09-07 2009-03-19 萬有製薬株式会社 Bicyclic aromatic substituted pyridone derivatives
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
BRPI0617621A2 (en) 2005-10-21 2011-08-02 Novartis Ag combination of organic compounds
JPWO2007049798A1 (en) 2005-10-27 2009-04-30 萬有製薬株式会社 New benzooxathiin derivatives
NZ568292A (en) 2005-11-10 2011-08-26 Msd Kk Spiro[cyclohexane-1,1'-(3'H)-4'-azaisobenzofuran]-4-carboxamide derivatives
CA2664113C (en) 2006-09-22 2013-05-28 Merck & Co., Inc. Use of platencin and platensimycin as fatty acid synthesis inhibitors to treat obesity, diabetes and cancer
EP2072519A4 (en) 2006-09-28 2009-10-21 Banyu Pharma Co Ltd Diaryl ketimine derivative
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2170930B3 (en) 2007-06-04 2013-10-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2714617A1 (en) 2008-03-06 2009-09-11 Banyu Pharmaceutical Co., Ltd. Alkylaminopyridine derivative
AU2009229860A1 (en) 2008-03-28 2009-10-01 Msd K.K. Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor
AU2009248914A1 (en) 2008-05-21 2009-11-26 Neurotez, Inc. Methods for Treating Neurodegenerative Disorders Related to Neurofibrillary Tangles
JP2011522828A (en) 2008-06-04 2011-08-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer, and other disorders
AU2009261248A1 (en) 2008-06-19 2009-12-23 Banyu Pharmaceutical Co., Ltd. Spirodiamine-diarylketoxime derivative
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
WO2010013595A1 (en) 2008-07-30 2010-02-04 萬有製薬株式会社 (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
CN102264228A (en) 2008-10-22 2011-11-30 默沙东公司 Novel cyclic benzimidazole derivatives useful for anti-diabetic agents
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2009313562B2 (en) 2008-11-04 2012-11-15 Neurotez, Inc. Leptin compositions and methods for treating progressive cognitive function disorders resulting from accumulation of neurofibrillary tangles and amlyoid beta
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379547A1 (en) 2008-12-16 2011-10-26 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
JP2012523434A (en) 2009-04-10 2012-10-04 アミリン・ファーマシューティカルズ，インコーポレイテッド Amylin agonist compounds for estrogen-deficient mammals
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR122021020041B1 (en) 2010-09-28 2023-03-07 Amylin Pharmaceuticals, Llc CHIMERIC POLYPEPTIDE, ITS USE AND COMPOSITION INCLUDING IT
PE20140859A1 (en) 2011-02-25 2014-07-25 Merck Sharp & Dohme NOVELTY DERIVATIVES OF CYCLIC AZABENZIMIDAZOLE USEFUL AS ANTIDIABETIC AGENTS
JP2015525782A (en) 2012-08-02 2015-09-07 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Antidiabetic tricyclic compounds
EP2958562A4 (en) 2013-02-22 2016-08-10 Merck Sharp & Dohme Antidiabetic bicyclic compounds
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP3004138B1 (en) 2013-06-05 2024-03-13 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
AU2015308350B2 (en) 2014-08-29 2020-03-05 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN113302189A (en) 2018-11-20 2021-08-24 Tes制药有限责任公司 Inhibitors of alpha-amino-beta-carboxyadipimic acid semialdehyde decarboxylating enzyme

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4626549A (en) * 1974-01-10 1986-12-02 Eli Lilly And Company Treatment of obesity with aryloxyphenylpropylamines

Also Published As

Publication number Publication date
JPH11501297A (en) 1999-02-02
CA2211656A1 (en) 1996-08-08
EP0836620A1 (en) 1998-04-22
WO1996023514A1 (en) 1996-08-08

Similar Documents

Publication Publication Date Title
AU4766196A (en) Anti-obesity proteins
AU4774496A (en) Anti-obesity proteins
AU4862096A (en) Anti-obesity proteins
AU4705196A (en) Anti-obesity proteins
AU4774696A (en) Anti-obesity proteins
AU4766096A (en) Anti-obesity proteins
EP0810871A4 (en) Anti-obesity proteins
AU7203496A (en) Novel peptides
AU5181296A (en) Anti-obesity proteins
AU4922497A (en) Interleukin-18-receptor proteins
AU5539596A (en) Anti-obesity agents
AU1115897A (en) Nima interacting proteins
AU4413096A (en) Phenylalanine free proteins
AU4427296A (en) Novel peptide
AU6873596A (en) Allergen-xcd32 fusion proteins
AU7294396A (en) Protein detection
AU4394396A (en) Modified peptides
GB9510830D0 (en) Proteins
AU3804995A (en) Melanoma-associated protein
AU2131195A (en) Prophenins - antibiotic peptides
AU5989696A (en) Tcr vbeta5 peptides
AU4396396A (en) Baby-bathing aid
AU7520396A (en) Abl-interactor protein
AU4843297A (en) Anti-obesity proteins
AU5284296A (en) Immune-evading proteins